Ticker: ADMA

ADMA Biologics, Inc. (NASDAQ: ADMA) has released its quarterly financial report for the period ending June 30, 2025. Here are the key points from the recent earnings statements and company developments. Revenue: Revenues reached $121.98 million for the three months ended June 30, 2025, reflectin...

ADMA Biologics, Inc. (NASDAQ: ADMA) is a U.S.-based biopharmaceutical company focused on developing and commercializing specialty biologics for individuals suffering from immunodeficiency. Recently, the company reported its quarterly results for the period ending March 31, 2025, indicating signif...